SCHEMBL5730241

SCHEMBL5730241

CSCc1cccc(Cl)c1NC(=O)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 6/20 0.50
PDK2 Q15119 6/20 0.50
PDK3 Q15120 6/20 0.50
PDK4 Q16654 6/20 0.50
L3MBTL1 Q9Y468 2/20 0.39
PTGS2 P35354 2/20 0.39
NLRP3 Q96P20 1/20 0.38
AKR1B10 O60218 1/20 0.37
UGT1A9 O60656 1/20 0.37
TRPA1 O75762 1/20 0.37
ABCB11 O95342 1/20 0.37
MT-CO2 P00403 1/20 0.37
TTR P02766 1/20 0.37
ALB P02768 1/20 0.37
CXCL8 P10145 1/20 0.37
UGT1A6 P19224 1/20 0.37
UGT1A1 P22309 1/20 0.37
PTGS1 P23219 1/20 0.37
CXCR1 P25024 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221540 0.82 PDK1 (0.51) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL1179119 0.80 PDK1 (0.67) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL5730232 0.80 PDK1 (0.49) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL15569990 0.74 PDK1 (0.55) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL2211292 0.71 PDK1 (0.51) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL10944821 0.70 L3MBTL1 (0.44) L3MBTL1PTGS2HPGD
SCHEMBL23060424 0.67 PDK1 (0.68) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL12666582 0.67 PDK1 (0.67) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL25095439 0.67 PDK1 (0.55) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL1145190 0.66 PNMT (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501826-B1 SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS HOFFMANN LA ROCHE (CH) 2006-09-27 EP disclosed
US-6852726-B2 Substituted indoles as alpha-1 agonists SYNTEX LLC (US) 2005-02-08 US disclosed
EP-1501826-A2 SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS F. Hoffman-la Roche AG (CH) 2005-02-02 EP disclosed
US-20030220319-A1 Substituted indoles as alpha-1 agonists SYNTEX (U.S.A.) LLC 2003-11-27 US disclosed
WO-2003064387-A2 SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS F. HOFFMAN-LA ROCHE AG (CH) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220319-A1 Substituted indoles as alpha-1 agonists ADRA1A, ADRB1, ADRA1B PDK1 4716/4885PDK2 4747/4885PDK3 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.